REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") announced today that it will present at the 21st Annual WORLDSymposiumtm 2025, held February 3-7, 2025, in San Diego, Calif. The poster presentations ...

Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will feature oral and poster presentations at the upcoming ...

JCR Pharmaceuticals Co., Ltd. (OTCMKTS:JCRRF – Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target of ...

Regenxbio has entered into a strategic collaboration worth $810m with Japan-based Nippon Shinyaku to advance gene therapies targeting the rare metabolic disorder mucopolysaccharidosis (MPS). Under the ...